Clin Osteol 2013; 18(4): 133-136

Diabetes mellitus 2. typu a kostReview articles

I. Raška

Diabetes mellitus and osteoporotic fractures are important causes of morbidity and mortality in elderly patients. Recently published studies have confirmed an increased risk of hip fractures and vertebral fractures in type 1 and also type 2 diabetes when compared to the healthy population. The etiopathogenic link between these chronic diseases is poorly understood. Increased bone fragility in pa­ tients with diabetes mellitus is caused by many factors such as advanced glycation end products, abnormal renal function, changes in insulin levels or the influence of some antidiabetic drugs. This article gives an overview of risk factors for developing bone metabo­ lism disorders in patients with type 2 diabetes.

Keywords: diabetes mellitus, osteoporosis, advanced glycation end products, bone quality

Published: December 11, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Raška I. Diabetes mellitus 2. typu a kost. Osteologický bulletin. 2013;18(4):133-136.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and de­ creased bone turnover, but no evident alteration of fracture susceptibility in elder­ ly women with diabetes mellitus. Osteoporos Int 2005;16:1506-1512. Go to original source...
    2. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 2007;18:427-444. Go to original source...
    3. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008; 93:1013-1019. Go to original source...
    4. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and the­ ir relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009;84:45-55. Go to original source...
    5. Petit MA, Paudel ML, Taylor BC, Hughes JM, Strotmeyer ES, Schwartz AV, Cauley JA, Zmuda JM, Hoffman AR, Ensrud KE. Osteoporotic Fractures in Men (MrOs) Study Group. Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. J Bone Miner Res 2010;25:285-291. Go to original source...
    6. Schwartz AV, Hillier TA, Sellmeyer DE, Resnick HE, Gregg E, Ensrud KE. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002;25:1749-1754. Go to original source...
    7. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a pos­ sible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 2010; 21:195-214. Go to original source...
    8. Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas PD, Garnero P. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentia­ tion. J Biol Chem 2007;282:5691-5703. Go to original source...
    9. Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. ffentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci 2008;1126:166-172. Go to original source...
    10. Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP. Influence of nonenzymatic glycation on biomechanical properties of cortical bo­ ne. Bone 2001;28:195-201. Go to original source...
    11. Paula FJ, Rosen CJ. Obesity, diabetes mellitus and last but not least, osteoporosis. Arq Bras Endocrinol Metabol 2010;54:150-157. Go to original source...
    12. Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR, Resnick HE, Tylavsky FA, Black DM, Cummings SR, Harris TB, Bauer DC. Health, Aging, and Body Composition Study. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009;94: 2380-2386. Go to original source...
    13. Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care 2009;32:2263-2268. Go to original source...
    14. Gaens KH, Ferreira I, van der Kallen CJ, van Greevenbroek MM, Blaak EE, Feskens EJ, Dekker JM, Nijpels G, Heine RJ, 't Hart LM, de Groot PG, Stehouwer CD, Schalkwijk CG. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab 2009;94:5174-5180. Go to original source...
    15. Yamagishi S. Advanced Glycation End Products and Receptor-Oxidative Stress System in Diabetic Vascular Complications. Ther Apher Dial 2009;13:534-539. Go to original source...
    16. Skrha J, Prázný M, Hilgertová J, Kvasnicka J, Kalousová M, Zima T. Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. Eur J Clin Pharmacol 2007;63:1107-1114. Go to original source...
    17. Eriksen EF, Eghbali-Fatourechi GZ, Khosla S. Remodeling and vascular spaces in bone. J Bone Miner Res 2007;22:1-6. Go to original source...
    18. Baynes KC, Boucher BJ, Feskens EJ, Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 1997;40:344-347. Go to original source...
    19. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004;79:820-825. Go to original source...
    20. Scragg R, Sowers M, Bell C. Third National Health and Nutrition Examination Survey. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2813-2818. Go to original source...
    21. Need AG, O'Loughlin PD, Horowitz M, Nordin BE. Relationship between fasting serum glucose, age, body mass index and serum 25 hydroxyvitamin D in postme­ nopausal women. Clin Endocrinol (Oxf) 2005;62:738-741. Go to original source...
    22. Hypponen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. Diabetes Care 2006;29:2244-2246. Go to original source...
    23. Campbell IT, Jarrett RJ, Keen H. Diurnal and seasonal variation in oral glucose tolerance: studies in the Antarctic. Diabetologia 1975;11:139-145. Go to original source...
    24. Behall KM, Scholfield DJ, Hallfrisch JG, Kelsay JL, Reiser S. Seasonal variation in plasma glucose and hormone levels in adult men and women. Am J Clin Nutr 1984;40:1352-1356. Go to original source...
    25. Ishii H, Suzuki H, Baba T, Nakamura K, Watanabe T. Seasonal variation of gly­ cemic control in type 2 diabetic patients. Diabetes Care 2001;24:1503. Go to original source...
    26. Johnson JA, Grande JP, Roche PC, Kumar R. Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am J Physiol 1994;267:356-360. Go to original source...
    27. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003;17:509-511. Go to original source...
    28. Billaudel B, Barakat L, Faure-Dussert A Vitamin D3 deficiency and alterations of glucose metabolism in rat endocrine pancreas. Diabetes Metab 1998;24:344-350.
    29. Bourlon PM, Billaudel B, Faure-Dussert A Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol 1999;160:87-95. Go to original source...
    30. Kadowaki S, Norman AW. Dietary vitamin D is essential for normal insulin se­ cretion from the perfused rat pancreas. J Clin Invest 1984;73:759-766. Go to original source...
    31. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980;209:823-825. Go to original source...
    32. Milner RD, Hales CN. The role of calcium and magnesium in insulin secretion from rabbit pancreas studied in vitro. Diabetologia 1967;3:47-49. Go to original source...
    33. Sooy K, Schermerhorn T, Noda M, Surana M, Rhoten WB, Meyer M, Fleischer N, Sharp GW, Christakos S. Calbindin-D(28k) controls [Ca(2+)](i) and insulin re­ lease. Evidence obtained from calbindin-d(28k) knockout mice and beta cell lines. J Biol Chem 1999;274:34343-34349. Go to original source...
    34. Riachy R, Vandewalle B, Moerman E, Belaich S, Lukowiak B, Gmyr V, Muharram G, Kerr Conte J, Jhttou F. 1,25-Dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. Apoptosis 2006;11:151-159. Go to original source...
    35. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla pro­ tein: vitamin K-dependent proteins in bone. Physiol Rev 1989;69:990-1047. Go to original source...
    36. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-469. Go to original source...
    37. Hinoi E, Gao N, Jung DY, Yadav V, Yoshizawa T, Myers MG Jr, Chua SC Jr, Kim JK, Kaestner KH, Karsenty G. The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol 2008;183:1235-1242. Go to original source...
    38. Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. J Musculoskelet Neuronal Interact 2008;8:351.
    39. Im JA, Yu BP, Jeon JY, Kim SH. Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta 2008;396:66-69. Go to original source...
    40. Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, Smith U, Mellstrom D. Plasma osteocalcin is inversely related to fat mass and plasma glu­ cose in elderly Swedish men. J Bone Miner Res 2009;24:785-791. Go to original source...
    41. Iki M, Tamaki J, Fujita Y, Kouda K, Yura A, Kadowaki E, Sato Y, Moon JS, Tomioka K, Okamoto N, Kurumatani N. Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Osteoporos Int 2012;23:761-770. Go to original source...
    42. Bulló M, Moreno-Navarrete JM, Fernández-Real JM, Salas-Salvadó J. Total and undercarboxylated osteocalcin predict changes in insulin sensitivity and cell func­ tion in elderly men at high cardiovascular risk. Am J Clin Nutr 2012;95:249-255. Go to original source...
    43. Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, Morales-Santana S, GarciaFontana B, Garcia-Salcedo JA, Munoz-Torres M. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:234-241. Go to original source...
    44. Hamann C, Rauner M, Hohna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Gunther KP, Stolina M, Han CY, Asuncion FJ, Ominsky MS, Hofbauer LC. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 2013;28: 627-638. Go to original source...
    45. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on re­ lative fracture risk. Diabetologia 2005;48:1292-1299. Go to original source...
    46. Schurman L, McCarthy AD, Sedlinsky C, Gangoiti MV, Arnol V, Bruzzone L, Cortizo AM. Metformin reverts deleterious effects of advanced glycation end-pro­ ducts (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 2008;116: 333-340. Go to original source...
    47. Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009;169:1395-1402. Go to original source...
    48. Grey A Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008;19:129-137.
    49. Benvenuti S, Cellai I, Luciani P, Deledda C, Baglioni S, Giuliani C, Saccardi R, Mazzanti B, Dal Pozzo S, Mannucci E, Peri A, Serio M. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 2007;30:26-30. Go to original source...
    50. Beck GR Jr, Khazai NB, Bouloux GF, Camalier CE, Lin Y, Garneys LM, Siqueira J, Jfeng L, Pasquel F, Umpierrez D, Smiley D, Umpierrez GE. The effects of thia­ zolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Transl Res 201;161(3): 145-155.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.